Investigational drug · Phase 2
FWD1802
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage IV.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "FWD1802"
First trial start
2023
Sep 12, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FWD1802", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer
- Breast Cancer Stage IV
- ER+/HER2- Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Locally Advanced Breast Cancer (LABC)
- ER+ Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "FWD1802" as an intervention, largest first.
Forward Pharmaceuticals Co., Ltd.Industry
NCT07002177 · 196 participants (planned) · Start Jun 1, 2025 · Primary completion May 1, 2028
Drug: FWD1802; Palbociclib 125mg and 3 more · For: Metastatic Breast Cancer; Breast Cancer Stage I; Breast Cancer Stage II and 2 more
Sites: Shanghai, China
Forward Pharmaceuticals Co., Ltd.Industry
NCT06064812 · 99 participants (planned) · Start Sep 12, 2023 · Primary completion Mar 2026
Drug: FWD1802 · For: Metastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancer Stage IV and 1 more
Sites: Hefei, China; Guangzhou, China; Huizhou, China · 22 sites in all
- Evaluation of the Food Effecton the Pharmacokinetics of FWD1802 in Healthy SubjectsActive, not recruiting
Forward Pharmaceuticals Co., Ltd.Industry
NCT07476963 · 18 participants (planned) · Start Mar 15, 2026 · Primary completion Jul 6, 2026
Drug: FWD1802 · For: Healthy
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Metastatic Breast Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- IpatasertibRO5532961, GDC-0068Phase 35 trials
Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- LasofoxifeneAZU-101Phase 34 trials
Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer
- TQB2930Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.